export const PDUFA_DATA = [
  {
    id: "static-1",
    company: "Merck & Co Inc.",
    ticker: "MRK",
    drug: "KEYTRUDA",
    pdufaDate: "2026-02-20",
    description: "FDA decision on KEYTRUDA plus chemotherapy with or without bevacizumab for treatment of patients with platinum-resistant recurrent ovarian cancer",
    category: "Oncology",
    status: "Pending",
    sourceUrl: "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    scrapedAt: "2026-02-10T00:00:00Z"
  },
  {
    id: "static-2",
    company: "VANDA PHARMACEUTICALS",
    ticker: "VNDA",
    drug: "Bysanti",
    pdufaDate: "2026-02-21",
    description: "FDA decision on Bysanti (milsaperidone) for the acute treatment of bipolar I disorder and the treatment of schizophrenia",
    category: "Neurology/Psychiatry",
    status: "Pending",
    sourceUrl: "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    scrapedAt: "2026-02-10T00:00:00Z"
  },
  {
    id: "static-3",
    company: "Eton Pharmaceuticals, Inc",
    ticker: "ETON",
    drug: "ET-600",
    pdufaDate: "2026-02-25",
    description: "FDA decision on ET-600 for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency",
    category: "Metabolic/Endocrine",
    status: "Pending",
    sourceUrl: "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    scrapedAt: "2026-02-10T00:00:00Z"
  },
  {
    id: "static-4",
    company: "Otsuka Holdings Co., Ltd.",
    ticker: "OTSKF",
    drug: "INQOVI",
    pdufaDate: "2026-02-25",
    description: "FDA decision on INQOVI plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy",
    category: "Oncology",
    status: "Pending",
    sourceUrl: "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    scrapedAt: "2026-02-10T00:00:00Z"
  },
  {
    id: "static-5",
    company: "Sanofi SA",
    ticker: "SNY",
    drug: "Dupixent",
    pdufaDate: "2026-02-28",
    description: "FDA decision on Dupixent in adults and children aged 6 years and older with allergic fungal rhinosinusitis (AFRS).",
    category: "Respiratory",
    status: "Pending",
    sourceUrl: "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    scrapedAt: "2026-02-10T00:00:00Z"
  },
  {
    id: "static-6",
    company: "Ascendis Pharma A/S",
    ticker: "ASND",
    drug: "TransCon CNP",
    pdufaDate: "2026-02-28",
    description: "FDA decision on TransCon CNP (navepegritide) for the treatment of children with achondroplasia",
    category: "Genetic/Rare Disease",
    status: "Pending",
    sourceUrl: "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    scrapedAt: "2026-02-10T00:00:00Z"
  }
];
